GILD vs. PFE: Gilead Sciences vs. Pfizer Stock Comparison

Company Profile

Gilead Sciences (GILD) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while PFE is classified in Pharmaceuticals.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Pfizer (PFE) reports 4.47%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Pfizer (PFE) reports 6.34%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Gilead Sciences (GILD) at 2.39% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Pfizer (PFE) at -3.55%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Pfizer (PFE) at 0.71 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and Pfizer (PFE) at 7.30% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Gilead Sciences (GILD) reports 43.46%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Gilead Sciences (GILD) at 6.68 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.

Pfizer (PFE) at 1.88 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics